<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>jmedicalcasereports</PublisherName>
      <JournalTitle>Frontiers in Medical Case Reports</JournalTitle>
      <PISSN>I</PISSN>
      <EISSN>S</EISSN>
      <Volume-Issue>Volume 2; Issue 3</Volume-Issue>
      <PartNumber/>
      <IssueTopic>Multidisciplinary</IssueTopic>
      <IssueLanguage>English</IssueLanguage>
      <Season>(May-Jun, 2021)</Season>
      <SpecialIssue>N</SpecialIssue>
      <SupplementaryIssue>N</SupplementaryIssue>
      <IssueOA>Y</IssueOA>
      <PubDate>
        <Year>-0001</Year>
        <Month>11</Month>
        <Day>30</Day>
      </PubDate>
      <ArticleType>Medical Case Reports</ArticleType>
      <ArticleTitle>Convalescent Plasma Therapy in SARS-COV-2 Infection, Experience in Tucum__ampersandsignaacute;n Argentina: An Observational Study</ArticleTitle>
      <SubTitle/>
      <ArticleLanguage>English</ArticleLanguage>
      <ArticleOA>Y</ArticleOA>
      <FirstPage>1</FirstPage>
      <LastPage>13</LastPage>
      <AuthorList>
        <Author>
          <FirstName>Rossana</FirstName>
          <LastName>Chahla</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>N</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Agote</FirstName>
          <LastName>Felicitas</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Medici</FirstName>
          <LastName>Natalia</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Agudo</FirstName>
          <LastName>Gabriela</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Farhat</FirstName>
          <LastName>Maria</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Sandoval Maria</FirstName>
          <LastName>Rosa</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>De Gorostiza</FirstName>
          <LastName>Graciela</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Valenzuela</FirstName>
          <LastName>Juan</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Amicone</FirstName>
          <LastName>Nancy</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Barrenechea</FirstName>
          <LastName>Guillermo</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Aguilar</FirstName>
          <LastName>Mónica</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Costas</FirstName>
          <LastName>Dardo</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Sigler</FirstName>
          <LastName>Walter</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Toledo</FirstName>
          <LastName>Roxana</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Maldonado</FirstName>
          <LastName>Carolina</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Cazorla Silvia</FirstName>
          <LastName>Inés</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Chehin</FirstName>
          <LastName>Rosana</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Ploper</FirstName>
          <LastName>Diego</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Vera Pingitore</FirstName>
          <LastName>Esteban</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Tomas Grau</FirstName>
          <LastName>Rodrigo</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Perdigón</FirstName>
          <LastName>Gabriela</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Peral María de los</FirstName>
          <LastName>Angeles</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
        </Author>
      </AuthorList>
      <DOI/>
      <Abstract>Background: Therapies based on different drugs and corticosteroids have been employed to stop the SARS-COV-2 virus infection. The administration of convalescent plasma (CP) is other therapy used to control COVID-19 disease. Aim: To evaluate the efficacy of the CP therapy on the recovery of SARS-COV-2 infection in 189 hospitalized patients who received this treatment during July to October 2020. Material and Methods: 189 patients with COVID-19 requiring hospitalization in the Intensive Care Unit (ICU) or mechanical ventilation, from the public hospital dependent on the Health Ministry of Tucum__ampersandsignaacute;n, Argentina, were selected to receive plasma. The Convalescent Plasma to be use in the transfusion therapy, was selected according the nucelocapside specific IgG antibody titer, measured by Abbott Architect SARS-CoV-2 assay. Results: We observed that early administration of CP, between3 to 5 days after hospitalization, to patients with moderate disease, was associated with a decrease in the mortality. In 27 patients from the Intensive Care Unit which required mechanical ventilation and 28 patients that presented several comorbidities, plasma administration was effective in 14 and 60% respectively. Conclusion: The results suggest that the favorable effect of CP would be related with the the period of time when plasma was administered to hospitalized patients and the severity of the disease. Early administration was a critical point to decrease the deaths of SARS-COV-2 infected patients.</Abstract>
      <AbstractLanguage>English</AbstractLanguage>
      <Keywords>Convalescent Plasma,SARS-COV-2,Therapy</Keywords>
      <URLs>
        <Abstract>https://www.jmedicalcasereports.org/ubijournal-v1copy/journals/abstract.php?article_id=13086&amp;title=Convalescent Plasma Therapy in SARS-COV-2 Infection, Experience in Tucum__ampersandsignaacute;n Argentina: An Observational Study</Abstract>
      </URLs>
      <References>
        <ReferencesarticleTitle>References</ReferencesarticleTitle>
        <ReferencesfirstPage>16</ReferencesfirstPage>
        <ReferenceslastPage>19</ReferenceslastPage>
        <References>Abdullah HM, Hama-Ali HH, Ahmed SN, Ali KM, Karadakhy KA, Mahmood SO, Mahmood ZH, Amin KQ, Atta PM, Nuradeen BE, Mohammed SH. Severe refractory COVID-19 patients responding to convalescent plasma a case series. Ann Med Surg 2020; 56: 125e7.&#13;
&#13;
Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P. PLACID Trial Collaborators. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ 2020; 371: m4232.&#13;
&#13;
Avendano-Sola C, Ramos-Martinez A, Munez-Rubio E, Ruiz-Antoran B, de Molina RM, Torres F, Fernandez-Cruz A, Callejas-Diaz A, Calderon J, Payares-Herrera C, Salcedo I. Convalescent Plasma for COVID-19: A multicenter, randomized clinical trial. medRxiv 2020.&#13;
&#13;
Benson AB, Moss M, Silliman CC. Transfusion-related acute lung injury (TRALI): a clinical review with emphasis on the critically ill. Br J Haematol 2009; 147: 431e43.&#13;
&#13;
Berbudi A, Rahmadika N, Tjahjadi Adi I, Ruslami R. Type 2 Diabetes and its Impact on the Immune System. Curr Diabetes Rev 2020; 16: 442-449.&#13;
&#13;
Bryan A, Pepper G, Wener M, Fink S, Morishima C, Chaudhary A, Jerome K, Mathias P, Greninger AL. Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho. J of Clinical Microbiology 2020; 58: e00941-20&#13;
&#13;
CaoW-C, Liu W, Zhang PH, Zhang F, Richardus JH. Disappearance of antibodies to SARS-associated coronavirus after recovery. N Engl J Med 2007; 357: 1162-1163.&#13;
&#13;
Casadevall A and Pirofski L. ‘The convalescent sera option for containing COVID-19.’ J Clin Invest 2020; 130: 1545e8.&#13;
&#13;
Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis 2020; 20: 398-400.&#13;
&#13;
Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH, Chan P, Wong KC, Leung CB, Cheng G. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005; 24: 44-46.&#13;
&#13;
Enzmann MO, Erickson MP, Grindeland CJ, Lopez SMC, Hoover SE, Leedahl DD. Treatment and preliminary outcomes of 150 acute care patients with COVID-19 in a rural health system in the Dakotas. Epidemiol Infect 2020; 148: 124.&#13;
&#13;
Erkurt MA, Sarici A, Berber I, Kuku I, Kaya E, Ozgand;uuml;l M. Life-saving effect of convalescent plasma treatment in covid-19 disease: clinical trial from eastern Anatolia. Transfus Apher Sci 2020; 102867.&#13;
&#13;
Ghosh S and Klein RS. Sex Drives Dimorphic Immune Responses to Viral Infections. J Immunol 2020; 198: 1782-1789.&#13;
&#13;
Hung IF, To KK, Lee CK, Lee KL, Chan K, Yan WW, Liu R, Watt CL, Chan WM, Lai KY, Koo CK. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus Infection. Clin Infect Dis 2011; 52: 447-56.&#13;
&#13;
Janiaud P, Axfors C, Schmitt AM, Gloy V, Ebrahimi F, Hepprich M, Smith ER, Haber NA, Khanna N, Moher D, Goodman SN. Association of Convalescent Plasma Treatment with Clinical Outcomes in Patients With COVID-19 A Systematic Review and Meta-analysis. JAMA 2021; 325: 1185-1195&#13;
&#13;
Jiang S and Du L. Effect of Low-Pathogenic Human Coronavirus-Specific Antibodies on SARS-CoV-2. Trends in Immunology 2020; 41: 853-854.&#13;
&#13;
Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, Kong Y, Ren L, Wei Q, Mei H, Hu C. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients with Severe and Life-threatening COVID-19: A Randomized Clinical Trial. JAMA 2020; 324: 460-470.&#13;
&#13;
Libster R, Pand;eacute;rez Marc G, Wappner D, Coviello S, Bianchi A, Braem V, Esteban I, Caballero MT, Wood C, Berrueta M, Rondan A. Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults. N Engl J Med 2021.&#13;
&#13;
Liva SM and. Voskuhl RR. Testosterone Acts Directly on CD4 T Lymphocytes to Increase IL-10 Production. The Journal of Immunology 2001; 167: 2060–2067.&#13;
&#13;
Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, Hu JL, Xu W, Zhang Y, Lv FJ, Su K. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med 2020; 26: 1200–1204.&#13;
&#13;
Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med 2006; 145: 599-609.&#13;
&#13;
Maiztegui JI, Fernandez NJ, de Damilano AJ. Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome. Lancet 1979; 2: 1216-1217.&#13;
&#13;
Marano G, Vaglio S, Pupella S, Facco G, Catalano L Liumbruno G, Grazzini G Convalescent plasma: new evidence for an old therapeutic tool? Blood Transfus 2016; 14: 152-1577&#13;
&#13;
Penna C, Mercurio V, Tocchetti C, PagliaroP Sex-Related Diferences in COVID-19 Lethality 2020https://dott-mts.campusnet.unito.it/do/home.plhttp://www.sirc-cardio.it.&#13;
&#13;
Rasheed AM, Fatak DF, Hashim HA, Maulood MF, Kabah KK, Abdulamir AS. The therapeutic potential of convalescent plasma therapy on treating critically-ill COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq. Infez Med 2020; 28: 357-366.&#13;
&#13;
Rebello CJ, Kirwan JP, Greenway FL. Obesity, the most common comorbidity in SARS-CoV-2: is leptin the link?. International Journal of Obesity 2020; 44: 1810–1817.&#13;
&#13;
Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, Bucci E, Piacentini M, Ippolito G, Melino G. COVID-19 infection: the perspectives on immune responses. Cell Death and; Differentiation 2020; 27: 1451–1454.&#13;
&#13;
Shibo J and Lanying D. Effect of Low-Pathogenic Human Coronavirus-Specific Antibodies on SARS-CoV-2. Trends in Immunology 2020; 41: 853-854.&#13;
&#13;
Simonovich VA, Burgos Pratx LD, Scibona P, Beruto MV, Vallone MG, Vand;aacute;zquez C, Savoy N, Giunta DH, Pand;eacute;rez LG, Sand;aacute;nchez MD, Gamarnik AV. PlasmAr Study Group. A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. N Engl J Med 2020; 384: 619-629&#13;
&#13;
Tanne JH. Covid-19: FDA approves use of convalescent plasma to treat critically ill patients. British Medical Journal 2020; 368:m1256.&#13;
&#13;
Tiberghien P, Lamballerie X, Morel P, Gallian P, Lacombe K, Yazdanpanah Y. Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how? Vox Sang 2020; 12926.&#13;
&#13;
Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644-648.&#13;
&#13;
Van Griensven J, Edwards T, de Lamballerie X, Semple MG, Gallian P, Baize S, Horby PW, Raoul H, Magassouba NF, Antierens A, Lomas C. Evaluation of convalescent plasma for Ebola virus disease in Guinea. N Engl J Med 2016; 374: 33-42.&#13;
&#13;
Wooding DJ and Bach H. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks Narrative Review. Clinical Microbiology and Infection 2020; 26: 1436-1446.&#13;
&#13;
Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med 2007; 357: 1450-1461.</References>
      </References>
    </Journal>
  </Article>
</ArticleSet>